APOC3 inhibition in FCS and severe hypertriglyceridemia

Name: APOC3 Inhibition in FCS and Severe Hypertriglyceridemia
Uploaded: 2026-09-09T04:00:00+00:00
Duration: 1 min 39 s
Description: Dr. Erik Stroes discusses APOC3 inhibition in familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia, focusing on its effects on triglycer

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Translating Evidence Into Practice: Myosin Inhibition Across the HCM Spectrum
Translating Evidence Into Practice: Myosin Inhibition Across the HCM Spectrum
CME/CE
Translating Evidence Into Practice: Myosin Inhibition Across the HCM Spectrum
Christian Schulze, MD, PhD; Ahmad Masri, MD, MS
0.75 credits
Christian Schulze, MD, PhD; Ahmad Masri, MD, MS
0.75 credits
From Evidence to Action: Advancing Care in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome
From Evidence to Action: Advancing Care in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome
CME/CE
From Evidence to Action: Advancing Care in Severe Hypertriglyceridemia and Familial Chylomicronemia Syndrome
Dr. Ioanna Gouni-Berthold, MD; Gerald Watts, MD, PhD
0.25 credits
Dr. Ioanna Gouni-Berthold, MD; Gerald Watts, MD, PhD
0.25 credits
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
Primary Care
EASD 2026: The Evolving PCP Role in Managing Patients With CKM Diseases
Ana Maria Cebrián-Cuenca, MD, PhD
Ana Maria Cebrián-Cuenca, MD, PhD
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
Endocrinology
Amylin Therapies: What's on the Horizon for Obesity and Metabolic Care?
Timothy Garvey, MD
Timothy Garvey, MD

APOC3 Inhibition in FCS and Severe Hypertriglyceridemia

Recommended

Title